Scholarlink

<p>In recent years, there has been increasing interest in the cardiovascular (CVD) risk associated with rheumatic diseases. This risk is more or less well documented for most autoimmune diseases and is also reflected in a&#xa0;large number of publications, not only in recommendations from the European Society of Rheumatology (EULAR) but also mentioned by the European Society of Cardiology as part of the ESC guidelines. Once the focus of interest has shifted, the question inevitably arises as to how this risk could be reduced, or whether there are specific limits for cholesterol in rheumatism patients, or whether blood lipids should be lowered at all. This article discusses the various aspects of lipid management in rheumatic diseases, such as the lipid paradox, the effects of DMARDs on lipids and also on cardiovascular outcome in rheumatic patients, as well as the effects of lipid-lowering therapy on the underlying rheumatic disease. Finally, considerations are given as to what modern lipid management in patients with rheumatological diseases could look like.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyperlipidämie und Rheuma

  • 期刊论文

  • 发表日期：

    2026年5月12日

查看全文
  • Boris Lindner

摘要

In recent years, there has been increasing interest in the cardiovascular (CVD) risk associated with rheumatic diseases. This risk is more or less well documented for most autoimmune diseases and is also reflected in a large number of publications, not only in recommendations from the European Society of Rheumatology (EULAR) but also mentioned by the European Society of Cardiology as part of the ESC guidelines. Once the focus of interest has shifted, the question inevitably arises as to how this risk could be reduced, or whether there are specific limits for cholesterol in rheumatism patients, or whether blood lipids should be lowered at all. This article discusses the various aspects of lipid management in rheumatic diseases, such as the lipid paradox, the effects of DMARDs on lipids and also on cardiovascular outcome in rheumatic patients, as well as the effects of lipid-lowering therapy on the underlying rheumatic disease. Finally, considerations are given as to what modern lipid management in patients with rheumatological diseases could look like.